HUMA Stock Analysis: Buy, Sell, or Hold?
HUMA - Humacyte, Inc. Common Stock
$0.70
-0.14 (-16.55%)
▼
5d:
-34.54%
30d:
-31.33%
90d:
-17.63%
WAIT
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When HUMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: HUMA is down 34.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: HUMA is down 34.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: HUMA is currently trading at $0.70, which is considered oversold relative to its 30-day fair value range of $0.91 to $1.35.
Technical Outlook: Technically, HUMA is in a strong downtrend. The price is currently testing key support at $1.10. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 16.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.05 (+192.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HUMA is in a strong downtrend. The price is currently testing key support at $1.10. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 16.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.05 (+192.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.91 -
$1.35
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-16.5%)
- BULLISH: Trading 192.7% below Wall St target ($2.05)
- WARNING: Recommendation downgraded due to -34.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.91 -
$1.35
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.10
Resistance Level
$1.53
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.92
Wall Street Target
$2.05
(+192.7%)
Revenue Growth (YoY)
-4.3%
Share & Embed Analysis
Last updated: June 24, 2026 6:04 AM ET
Data refreshes hourly during market hours. Next update: 7:04 AM
Data refreshes hourly during market hours. Next update: 7:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HUMA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 57 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
12 analysts |
$139 | 65 BUY |
